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TNFa R2Abstract Verapamil is a calcium channel blocker that belongs to the phenylalkylamine group. It
has been clinically used for various diseases such as combating hypertension, ischemic heart dis-
eases, supraventricular antiarrhythmic and tycolysis. The study was conducted to investigate the
effect of verapamil on selected pro- and apoptotic factors during prenatal retinal differentiation
of mice at E14 and E17 of gestation. The pregnant females were classified into two groups, the first
is the control and the second receives SC injection of repeated doses of verapamil (40 mg/kg) at the
7th day of gestation. The pregnant females were sacrificed at E14 and at E17 of pregnancy and their
ocular regions were separated. The retina of mentioned ages were examined at histological and
immunohistochemistry of Cytochrome C, Caspase-3 as a pro-apoptotic; Bak and TNFa R2 as
apoptotic factors that engaged in proper normal development. The present findings revealed that
verapamil-treatment exhibited comparative thinning of inner plexiform layer and reduction of
nuclear in E14 and missing of the ganglion layer and comparative decrease of nuclear cells of
E17 comparing to the control. Also, the expression of Cytochrome C, Caspase-3, Bak and TNFa
R2 in the developing retina was obviously inhibited in verapamil-treatment at E17 compared to the
control group. The study concluded that verapamil, as a calcium channel blocker, has the ability to
alter the histology of the retina and suppress the studied markers resulting in disorganization of the
eye during prenatal development.
 2016 The Egyptian German Society for Zoology. Production and Hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
It is well known that calcium plays an integrated and crucial
role in regulation of cellular movement and transport, electri-
cal activation of excitable cells and various enzymatic reactionsthroughout the body (Rasmussen, 1986). Calcium is almost a
universal intracellular messenger controlling diverse ranges of
cellular processes such as gene transcription, muscle contrac-
tion, cell proliferation and activating different intracellular
biochemical processes in response to extracellular stimuli
(Bootman et al., 2001). Extracellular calcium has an important
role in cell–cell adhesion in mammalian embryos during
pre-implantation process. Also, intracellular free ionized cal-
cium plays a key role in fertilization, oocyte maturation/and
Figure 1 Photomicrographs of the developing eye at E14 of the control (A and C) and verapamil-treated (B and D) showing similarity of
the developing structures. F and H eye of verapamil-treated embryos at E17 showing degenerated retina compared to the control (E and
G). Cornea (C), lens (L), retina (R), neural layer (NL), neuroblastic layer (NBL), ganglion cell layer (GCL), plexiform layer (PL),
inflammatory cells (arrows). H and E stain scale bar 10 lm (A, B, E, F); 50 lm (C, D, G, H).
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Whitaker, 2008).
Verapamil, a calcium channel blocker given either in vivo or
in vitro, has the ability to inhibit calcium uptake (Goligorsky
et al., 1985). It belongs to the phenylalkylamines that are used
clinically for combating hypertension, ischemic heart diseases,
supraventricular tachyarrhythmias and tycolysis (Dong-Yun
et al., 2010). It also an active antianginal, antiarrhythmic
and antihypertensive that is used in the treatment of cardiovas-
cular diseases (Johnston et al., 1981; Lu¨llmann et al., 2003) and
improve abnormal left ventricular diastolic relaxation in
patients with hypertrophic cardiomyopathy (Hanrath et al.,1980; Bonow et al., 1981; Lorell et al., 1980, 1982). Verapamil
has also neuroprotective effect in several acute neurotoxicity
(Liu et al., 2011) and nephroprotective effect against lead
and cadmium toxicity (Lermioglu and Bernard, 1998; Zhang
et al., 2013). In addition, verapamil has antiproliferative effect
on the tumor cell both in vivo and in vitro (Schmidt et al., 1988;
Jian et al., 2007). Moreover, verapamil was recently used in the
treatment of waste and surface waters (Khan and Ongerth,
2004; Hummel et al., 2006; Batt et al., 2008). Hence, the study
was conducted to evaluate the effect of insufficient calcium due
to verapamil treatment in pregnant mice on the histogenesis of
the retina and to evaluate the effect on Cytochrome-C,
Figure 2 Photomicrographs of immunoreactivity of cytochrome C during eye development showing downregulated expression of
control from E14 to E 17 that was restricted to the ganglion layer and the basement membrane of the neuroblastic layer (A, C, E, G).
Verapamil treated embryos show the same expression at E14 (B and D), downregulation at E17 that disappeared in the ganglion layer and
in the basement membrane of the neuroblastic layer of the retina (H), arrows, compared to the control. Cornea (C), lens (L), retina (R),
neural layer (NL), neuroblastic layer (NBL). Scale bar 10 lm (A, B, E, F); 50 lm (C, D, G, H).
30 A.A. Seleem, Fakhr El-Din M. LasheinCaspase-3 as pro-apoptotic factors; BAK (an apoptotic mem-
ber of Bcl2 family) and TNFa R2 receptor those incorporated
in normal developmental processes during embryogenesis.
Materials and methods
Verapamil was obtained from Sigma Aldrich company USA.
Adult female and male mice Mus musculus (weighting
25–30 g) were used. The animals were obtained from a closed
random bred colony at Faculty of medicine, Assuit university,
Egypt. The mice were maintained on food and water ad libitumand housed in groups in isolated cages. The animals were accli-
matized for 2 weeks prior to usage. Females mice with regular
estrous cycle were obtained after repeated vaginal examina-
tion. Estrous females were paired overnight with well proven
fertile males. On the next morning, vaginal plugs were exam-
ined, when zero day of pregnancy was determined. The preg-
nant females were divided into two groups (n= 10), the first
is the control, and the second group receives repeated SC injec-
tions of verapamil (40 mg/kg) at the 7th day of pregnancy. The
selected period of drug administration at the 7th day up to the
17th day of gestation is considered as the most sensitive period
of gestation to any adverse insult (Christian, 2001). Pregnant
Figure 3 Photomicrographs of immunoexpression of caspase-3 during prenatal eye development in control at E14 (A and C) in all eye
structures and retina that increased in verapamil treated embryos (B and D). Restricted intense expression was noted in the ganglion and
the plexiform of control at E17 (E and G) that was inhibited in verapamil treated embryos of the same age (F and H). Cornea (C), lens (L),
retina (R), neural layer (NL), neuroblastic layer (NBL), plexiform layer (PL), ganglion cell layer (GCL). Scale bar 10 lm (A, B, E, F);
50 lm (C, D, G, H).
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experimental animals in this study was conducted under the
guidance of the basic standards in the care and use of labora-
tory animals, which has been prepared and published by the
institutional animal care committee. Eyes at E14 and E17 of
the control and treated groups were fixated in Caryno’s fixa-
tive, dehydrated in ethyl alcohol, cleared in methyl benzoate
and processed for sectioning. 5l thick sections were stained
with hematoxylin and eosin for general histology (Drury and
Wallnigton, 1976).
For immunohistochemical investigation, sections were
mounted on Superfrost/Plus glass slides. The slides weredeparaffinized in xylene, rehydrated and retrieved for re-
antigenicity using 10 mM citrate buffer at pH 6 in 100 C for
an hour (Buchlowalow and Bocker, 2010). Sections were incu-
bated with specific primary antibody against anti-Caspase 3
(Rabbit-polyclonal antibody, NeoMarkers, Fremont. CA,
USA) at dilution (1:100); anti-TNFa-R2 (Rabbit polyclonal,
spring, Bioscience, USA) at dilution (1:100);-Cytochrome C
(mouse monoclonal antibody, Santa Cruz, Biotechnology,
INC., Germany) at dilution (1:100) and anti-BAK (rabbit
polyclonal antibody, Santa Cruz, Biotechnology, INC., Ger-
many) at dilution (1:100), for three hours at room temperature.
Sections were then washed using phosphate buffer and incu-
Figure 4 Photomicrographs of the immunostained sections of the developing retina at E14 (A and C) and at E17 (E and G) of the
control showing restricted expression of BAK at the developing ganglion cell layer (GCL). Restricted expression of BAK at the neural
layer in E14 (B and D) and inhibition of BAK expression at E17 (F and H) was noted in verapamil treated embryos (arrows). Scale bar
10 lm (A, B, E, F); 50 lm (C, D, G, H).
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polyvalent HRP DAB detection system, Spring Bioscience,
USA). Then sections were washed with phosphate buffer and
then visualized with chromogen solution that contained
0.05% 30,30-diaminobenzadine. Stained sections were mounted
with DPX mounting media and investigated under a light
microscope.
Results
At E14-old embryos the eye has a well developed cornea, lens
and retina with differentiated neural and neuroblastic layers(Fig. 1A and C). At E17, ganglion cell layer and a plexiform
layer were differentiated in addition to the remaining neurob-
lastic layer (Fig. 1E and G). In verapamil treatment, the histo-
logical structure of the developing eye at E14 is similar to that
of control (Fig. 1B and D). At E17, the effect of verapamil was
clearly manifested. The inner surface of the neuroblastic layer
was infiltrated with inflammatory cells with de-differentiation
of either the ganglion or the plexiform layers, also there was
comparatively missing of ganglion cells and an apparent reduc-
tion of nuclear cell densities (Fig. 1F and H). In control E14,
over-expression of cytochrome C was detected at the periphery
and inner margin of the nuclear layer (Fig. 2A and C), how-
ever verapamil-treatment possessed comparatively less
Figure 5 Photomicrographs of the immunostained sections of the developing retina at E14 (A and C) and at E17 (E and G) of the
control showing restricted expression of TNFa R2 at the developing ganglion cell layer (GCL). Restricted expression of TNFa R2 at the
neural layer in E14 (B, D) and inhibition of TNFa R2 expression at E17 (F and H) was noted in verapamil treated embryos (arrows). Scale
bar 10 lm (A, B, E, F); 50 lm (C, D, G, H).
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Comparing with control E17, the ganglion cell and inner mar-
gin of the nuclear layer showed decreased expression of cyto-
chrome c (Fig. 2F and H). Concerning caspase3, verapamil-
treatment at E14 (Fig. 3B and D) exhibited moderate
immunostaining throughout the nuclear layer and was highly
expressed in its peripheral and inner margins, comparing with
the negative reaction in the control (Fig. 3A and C). In the
developing retina, the expression is homogenous that was best
detected in the basement membrane of the neuroblastic layer
of the control (Fig. 3C) and increased in verapamil treated
embryos (Fig. 3D). In older embryos at E17 of development,
the expression is restricted to the differentiated ganglion andthe plexiform layers of control embryos (Fig. 3E and G) that
were inhibited in verapamil treated embryos (Fig. 3F and H)
compared to the control.
The expression of both BAk and TNFa R2 are the least of
the studied factors. The normal immunoexpression of BAK in
the control group showed weak expression at E14 in NBL and
NL (Fig. 4A and C) that gradually increases and best detected
GCL at E17 (Fig. 4E and G). In verapamil treated embryos,
similar expression was noted at E14 (Fig. 4B and D) while
no expression was noted at E17 of verapamil treated embryos
as compared to the control (Fig. 4F and H). TNFa R2 recep-
tor expression was confined to the developing ganglion cell
layer in the control embryo at E14 (Fig. 5A and C) and at
34 A.A. Seleem, Fakhr El-Din M. LasheinE17 (Fig. 5E and G). Verapamil treated embryos at E14
(Fig. 5B and D) didn’t showed any change in expression while
developing ganglion showed inhibition of the TNFa R2 recep-
tor expression at E17 (Fig. 5F and H).
Discussion
The present investigation revealed that verapamil (a calcium
channel blocker) exerts histological damage and alters the
expression of the pro- and apoptotic factors under investiga-
tion. Since earlier, calcium channel blockers are widely pre-
scribed for therapeutic purposes and some have been
recommended for use during pregnancy for defined indica-
tions; e.g. verapamil for treating fetal paroxysmal tachycardia
(Wolff et al., 1980; Lilja et al., 1984; Truccone and Mariona,
1985) and during tocolytic therapy (Strigl et al., 1981). These
therapeutic uses of calcium channel blockers are recommended
at late pregnancy after organogenesis has already been com-
pleted (Stein et al., 1990). Calcium channel blockers have been
shown in animal experiments to induce teratogenic effects and
to increase the incidence of embryolethality in mammalian ani-
mals (Lee and Nagele, 1986; Stein et al., 1990; Robert et al.,
2011; Uslu et al., 2013). In addition, verapamil causes malfor-
mations, edemas and reduced heart rate in the embryos, larvae
and adult fish (Rottbauer et al., 2001; Shin et al., 2010;
Steinbach et al., 2013). Verapamil inhibits glucose uptake in
insulin-sensitive tissues such as adipocyte skeletal myocytes
and cardiac myocytes (Khil et al., 1997; Whitehead et al.,
2001;Tenharmsel et al., 2005). Verapamil also inhibits the glu-
cose transport activity of GLUT 1 in a dose-dependent manner
(Larry et al., 2010). These effects of verapamil are consistent
with the retinopathy induced by verapamil treatment in preg-
nant animals of this study. The retinopathy of the retina can
be attributed mainly to calcium disturbance induced by vera-
pamil that may cause a decrease in cell adhesion and alteration
of the ionic coupling of retinal cells during differentiation. In
this context, verapamil was found to diffuse through the pla-
centa resulting in low blood concentration of the developing
embryo than in maternal blood (Solans et al., 2000). In addi-
tion, verapamil was also shown to induce miscarriages via
inhibiting implantation at high doses (Uslu et al., 2013).
Immunohistochemical investigation revealed the expression
of the pro-apoptotic factors (cytochrome c and caspase-3) in
normal development of the retina at pre-natal stages at E14,
E17 of gestation. Immunoexpression of these two factors
reflect their role in normal development regardless the effect
of verapamil on calcium uptake of the developing retina cells.
Also, the expression of BAK and TNFa R2 in normal retinal
differentiation however was restricted to the differentiated
nerve fibers of the ganglion neural layer and also reflects their
role in normal development regionally in contrast to the
expression of the other two factors that coincides with the dif-
ferent regions of the developing retina. Of these factors, the
pro-apoptotic factor (caspase-3) expression is the only of the
studied factors that increased especially at E14 of prenatal
development as a result of verapamil treatment that results
in the damage and de-differentiation of the retinal layers. In
normal development the role of both the pro-and apoptotic
factors under investigation was reported (Liu et al., 1996;
Tezel et al., 2001; Hahn et al., 2003; Zeiss et al., 2004;
Abdul-Ghani and Megeney, 2008). This confirm the resultsobtained at E17 of the retinal development as a result of vera-
pamil treatment since the ganglion and the plexiform layers
were deformed in the retina of downregulated expression of
all the studied factors. Programed cell death (apoptosis) is cru-
cial for the normal development of the retina and it is a tight
orchestrated event under control of genetic programs. Vecino
et al. (2004) explain the typical signaling pathways which lead
to cell apoptosis in the developing vertebrate retina that
involved the studied markers and clarified their roles during
retina development. From the other hand suppression of nor-
mal apoptosis in verapamil treatment was recorded in several
studies (Zawadzki et al., 2008; Wyska, 2009; Mei-Ping et al.,
2011). Alteration of normal apoptosis as well the normal
development of the retina in the present study result from
the downregulation as in the case of cytochrome c; BAK and
TNF R2 or the elevation of caspase-3 expression in
verapamil-treated embryos that exert a drastic effect on the
ganglion cell layer in the present study. From the previous
and the present studies it can be concluded that verapamil as
a calcium channel blocker has the ability to alter the normal
apoptosis during prenatal retinal differentiation of mice
through downregulation of cytochrome c; BAK; TNF R2
and upregulation of caspase-3 that results in a drastic effect
on the developing retina regardless the intra- or extracellular
calcium ion concentration.
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